In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLCs registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Cure For The Flu: Orphan Drug-Like Incentives, Tissue-Based Production

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency plans to request congressional action on influenza vaccine incentives during three hearings on the flu vaccine shortage. FDA, in cooperation with U.K. regulatory officials, will determine in January whether Chiron will be able to manufacture Fluvirin at the company’s Liverpool facility for the 2005-06 flu season.

You may also be interested in...



Cell-Culture Manufacturing Key To Boosting Flu Vaccine Supply, FDA Says

Congress’ top priority in strengthening the flu vaccine supply should be funding research in cell-cultured manufacturing, FDA Acting Commissioner Crawford tells Senate committee. However, even with cell-culture technology, flu vaccine market is unlikely to regain all of its previous suppliers, he suggests.

Cell-Culture Manufacturing Key To Boosting Flu Vaccine Supply, FDA Says

Congress’ top priority in strengthening the flu vaccine supply should be funding research in cell-cultured manufacturing, FDA Acting Commissioner Crawford tells Senate committee. However, even with cell-culture technology, flu vaccine market is unlikely to regain all of its previous suppliers, he suggests.

FDA's Crawford Readies Himself For "Intense Week" Of Congressional Hearings

FDA Acting Commissioner Lester Crawford will appear in front of four congressional committees this week in what amounts to "the most intense week of congressional hearings that we have had in FDA's history," he said

Related Content

Topics

UsernamePublicRestriction

Register

PS058127

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel